Fusion Pharmaceuticals Inc. Depreciation and Amortization Expense
Fusion Pharmaceuticals Inc. reported Depreciation and Amortization Expense of $1.30 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-20.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DepreciationAndAmortization · last filed 2024-03-20
- Fusion Pharmaceuticals Inc. depreciation, depletion and amortization, nonproduction for fiscal 2023 was $1.30M, a 44.44% increase from fiscal 2022.
- Fusion Pharmaceuticals Inc. depreciation, depletion and amortization, nonproduction for fiscal 2022 was $900.00K, a 50.00% increase from fiscal 2021.
- Fusion Pharmaceuticals Inc. depreciation, depletion and amortization, nonproduction for fiscal 2021 was $600.00K, a 20.00% increase from fiscal 2020.
- Fusion Pharmaceuticals Inc. depreciation, depletion and amortization, nonproduction for fiscal 2020 was $500.00K, a 66.67% increase from fiscal 2019.
| Period end | Depreciation, Depletion and Amortization, Nonproduction 12 month |
|---|---|
| 2023-12-31 | $1.30M 10-K · filed 2024-03-20 |
| 2022-12-31 | $900.00K 10-K · filed 2024-03-20 |
| 2021-12-31 | $600.00K 10-K · filed 2023-03-16 |
| 2020-12-31 | $500.00K 10-K · filed 2022-03-17 |
| 2019-12-31 | $300.00K 10-K · filed 2021-03-25 |